Von Willebrand factor expression in osteosarcoma metastasis

Modern Pathology

Volumn 18, Issue 3, 2005, Pages 388-397

  Eppert, Kolja ^a,b   Wunder, Jay S ^a,b   Aneliunas, Vicky ^a   Kandel, Rita ^a,b   Andrulis, Irene L ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gene expression; Gene expression profiling; Metastasis; Neovascularization; Osteosarcoma; Von willebrand factor

Indexed keywords

MESSENGER RNA; VON WILLEBRAND FACTOR;

ARTICLE; CANCER GROWTH; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MEGAKARYOCYTE; OSTEOSARCOMA; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VON WILLEBRAND FACTOR;

EID: 15444376388     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800265     Document Type: Article

References (56)

1. Womer R. The cellular biology of bone tumors. Clin Orthop Relat Res 1991;262:12-21.
2. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-26.
3. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
4. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917.
5. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-141.
6. Ladanyi M, Gorlick R. Molecular pathology and molecular pharmacology of osteosarcoma. Pediatr Pathol Mol Med 2000;19:391-413.
7. Boehm AK, Neff JR, Squire JA, et al. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Pediatr Pathol Mol Med 2000;19: 359-376.
8. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001;92: 2181-2189.
9. Wunder JS, Eppert K, Burrow SR, et al. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 1999;18:783-788.
10. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990;50: 6130-6138.
11. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
12. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 1996;72:341-348.
13. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993;7:308-316.
14. McComb RD, Jones TR, Pizzo SV, et al. Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. J Histochem Cytochem 1982;30:371-377.
15. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-180.
16. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91:22-36.
17. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984;63:55-63.
18. Gasic GJ, Gasic TB, Galanti N, et al. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973;11:704-718.
19. Karpatkin S, Pearlstein E, Ambrogio C, et al. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988;81:1012-1019.
20. Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-1300.
21. Dahlin DC. Grading in bone tumors. In: Unni KK (ed). Bone Tumors. Churchill Livingstone: New York, 1988, pp 35-45.
22. Hopyan S, Gokgoz N, Bell RS, et al. Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours. J Orthop Res 1999;17:633-638.
23. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-971.
24. Bauer D, Muller H, Reich J, et al. Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR). Nucleic Acids Res 1993;21:4272-4280.
25. Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991;30:253-269.
26. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2000;18: 2685-2694.
27. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
28. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94: 883-893.
29. Ohsawa M, Tomita Y, Kuratsu S, et al. Angiogenesis in malignant fibrous histiocytoma. Oncology 1995;52: 51-54.
30. Tomlinson J, Barsky SH, Nelson S, et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999;5:3516-3522.
31. Yudoh K, Kanamori M, Ohmori K, et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84:1610-1615.
32. Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. Am J Pediatr Hematol Oncol 2001;23:286-289.
33. Zanetta L, Marcus SG, Vasile J, et al. Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer 2000;85:281-288.
34. Aird WC, Edelberg JM, Weiler-Guettler H, et al. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997;138:1117-1124.
35. Yamamoto K, de Waard V, Fearns C, et al. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood 1998;92: 2791-2801.
36. Kohlberger PD, Obermair A, Sliutz G, et al. Quantitative immunohistochemistry of factor VIII-related antigen in breast carcinoma: a comparison of computer-assisted image analysis with established counting methods. Am J Clin Pathol 1996;105: 705-710 (see comments).
37. Martin L, Green B, Renshaw C, et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997;76:1046-1054.
38. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147: 9-19 (comment).
39. Goddard JC, Sutton CD, Furness PN, et al. A computer image analysis system for microvessel density measurement in solid tumours. Angiogenesis 2002;5: 15-20.
40. Chantrain CF, DeClerck YA, Groshen S, et al. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem 2003;51:151-158.
41. Shevde LA, Welch DR. Metastasis suppressor pathways-an evolving paradigm. Cancer Lett 2003;198: 1-20.
42. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants or both? Cell 2003;113:821-823.
43. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-549.
44. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992;52:3267-3272.
45. Nierodzik ML, Plotkin A, Kajumo F, et al. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991;87:229-236.
46. Chiang HS, Yang RS, Huang TF. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells. Br J Cancer 1995;71:265-270.
47. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995;74: 282-290.
48. Chopra H, Hatfield JS, Chang YS, et al. Role of tumor cytoskeleton and membrane glycoprotein IRGpIIb/IIIa in platelet adhesion to tumor cell membrane and tumor cell-induced platelet aggregation. Cancer Res 1988;48:3787-3800.
49. Boukerche H, Berthier-Vergnes O, Tabone E, et al. Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood 1989;74: 658-663.
50. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelet integrin GPIIb-GPIIIa, fibronectin, von Willebrand factor, and thrombin in platelet-tumor interaction in vitro and metastasis in vivo. Semin Hematol 1994; 31:278-288.
51. Kitagawa H, Yamamoto N, Yamamoto K, et al. Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells. Cancer Res 1989;49:537-541.
52. Chopra H, Timar J, Rong X, et al. Is there a role for the tumor cell integrin alpha lib beta 3 and cytoskeleton in tumor cell-platelet interaction? Clin Exp Metast 1992;10:125-137.
53. Mehta P, Lawson D, Ward MB, et al. Effect of human tumor cells on platelet aggregation: potential relevance to pattern of metastasis. Cancer Res 1987;47: 3115-3117.
54. Clezardin P, Serre CM, Trzeciak MC, et al. Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction. Cancer Res 1991;51:2621-2627.
55. Clezardin P, Drouin J, Morel-Kopp MC, et al. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells. Cancer Res 1993;53:4695-4700.
56. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-431.